Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POINT: Ponesimod Add-on to DMF in Active Relapsing MS
NCT02907177Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2017
- Primary completion
- Mar 2020
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Ponesimod + DMF with Placebo + DMF (2 arms). Primary endpoint: Annualized Confirmed Relapse Rate. Started Mar 2017; status: terminated.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02907177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907177.